Cardiotoxicity of imatinib: At the heart of the problem

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 36-37

  Tiribelli, Mario ^a   Medeot, Marta ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DASATINIB; IMATINIB; LAPATINIB; NILOTINIB; SORAFENIB; SUNITINIB;

CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOTOXICITY; DIARRHEA; DISEASE MARKER; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; FLUID RETENTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HUMAN; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT PROLONGATION; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; HEART; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES;

EID: 78650179597     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.09.021     Document Type: Editorial

References (17)

1. Hochhaus A., O'Brien S.G., Guilhot F., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
2. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
3. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med 2006, 355:2408-2417.
4. Kerkelä R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.
5. Wolf A., Couttet P., Dong M., et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res 2010, 34:1180-1188.
6. Hatfield A., Owen S., Pilot P.R. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007, 13:13.
7. Atallah E., Durand J.B., Kantarjian H., Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007, 110:1233-1237.
8. Rosti G., Martinelli G., Baccarani M. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007, 13:14.
9. Verweij J., Casali P.G., Kotasek D., et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007, 43:974-978.
10. Trent J.C., Patel S.S., Zhang J., et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010, 116:184-192.
11. Gambacorti-Passerini C., Tornaghi L., Franceschino A., Piazza R., Corneo G., Pogliani E. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007, 13:14.
12. Breccia M., Cannella L., Frustaci A., Stefanizzi C., Levi A., Aliemena G. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: a single institution experience. Leuk Res 2008, 32:835-836.
13. Tiribelli M., Colatutto A., Marin L., et al. Brain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. Am J Hematol 2008, 83:517-518.
14. Marcolino M.S., Ribeiro A.L., Clementino N.C.D., et al. The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia. Leuk Res 2011, 10.1016/j.leukres.2010.07.011.
15. Estabragh Z.R., Knight K., Watmough S.J., et al. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res 2011, 35:49-51.
16. Yeh E.T.H., Bickforf C.L. Cardiovascular complications of cancer therapy. J Am Coll Cardiol 2009, 53:2231-2247.
17. Talpaz M., Shah N., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.